HepatoChem has developed a proprietary chemistry platform that enables cost-effective production of metabolites from bioactive small molecules. Its technology allows assessment of critical metabolite and toxicity issues relatively early in the R&D continuum, aiming to reduce the risk of failure in clinical development of drug candidates. The company is led by President Marc Bazin and is a member of the Biotech InnoVenture Center (BIVC) in Beverly. HepatoChem was founded in 2008 and is based in Beverly, Massachusetts. In April 2012 the company received a $330k loan from the Massachusetts Life Sciences Center as part of the MLSC 2012 Accelerator Program. HepatoChem is a Cambridge, MA-based company that provides pharmaceutical and biotech companies access to small-molecule metabolites in quantities needed for drug development. The company has developed a platform that uses biomimetic catalysts to mimic the metabolic function of the liver, developed in collaboration with Professor John Groves at Princeton University. The technology is designed to enable quicker and more cost-effective production of metabolites. HepatoChem is led by founder and CEO Marc Bazin. The company intends to use recently received funds to commercialize its technology. As of the article, HepatoChem received a $100K initial investment from Heartland Bridge Capital, which intends to provide up to $400K of equity capital.

Total raised

$0M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Apr 2012